Showing 3801-3810 of 9148 results for "".
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- AAD Elects New Officers, Board Membershttps://practicaldermatology.com/news/aad-elects-new-officers-board-members/2460358/Mark D. Kaufmann, MD, FAAD, has been elected to lead the American Academy of Dermatology. He will be installed as president-elect in March 2021 and hold the office of president for one year beginning in March 2022. Dr. Kaufmann, who is a member of the Practical Dermatology®
- Cynosure Enters the Muscle Toning Market in Europe, Middle Easthttps://practicaldermatology.com/news/cynosure-enters-the-muscle-toning-market-in-europe-middle-east/2460200/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acqui
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washing
- PD1 Blocker Shrinks Advanced Squamous Cell Skin Cancershttps://practicaldermatology.com/news/pd1-blocker-shrinks-advanced-squamous-cell-skin-cancers/2457737/A checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of squamous cell carcinoma, an international team reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of pa
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile
- American Telemedicine Association Names New Vice Chair of Teledermatologyhttps://practicaldermatology.com/news/american-telemedicine-association-names-new-vice-chair-of-teledermatology/2458616/Mark P. Seraly, MD, founder and chief medical officer of Iagnosis, a developer of telemedicine solutions and the creator of DermatologistOnCall, has been elected Vice Chair of the Teledermatology Special Interest Group of the American Telemedicine Association (ATA) the leading international resou
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat